Bulletin
Investor Alert

Topics

Medicine and Health

4:04 a.m. July 1, 2021 - By Jaimy Lee
Novavax's experimental COVID-19 shot has 86.4% efficacy against the Alpha variantShares of Novavax Inc. were up 2.5% in premarket trading on Thursday, the day after The New England Journal of Medicine published a looking at how Novavax's COVID-19 vaccine candidate performed in a Phase 3 clinical trial conducted in 15,000 participants in the U.K. An earlier analysis of the data was previously published as a preprint. According to the new study, Novavax's experimental vaccine has an overall efficacy rate of 96.4% against the original strain of the virus and an 86.3% efficacy rate against the Alpha variant, which was first identified in the U.K. and has been the most dominant form of the virus in many countries since the start of the year. Novavax did not mention the Delta variant, which is now the most dominant form of the virus in the U.K., in this study. The company is conducting separate studies of its experimental shot in the U.S. Novavax's stock is up 90.4% for the year, while the broader S&P 500 has gained 14.4%.
7:50 a.m. Jan. 21, 2021 - By Ciara Linnane
Biden signs flurry of orders to tackle pandemic that has now cost more than 407,000 American lives Fauci addresses board of World Health Organization with promise that U.S. will join international response to crisisThe global case tally for the coronavirus-borne illness COVID-19 edged above 97 million on Thursday with the U.S. accounting for 24 million of those cases, as President Joe Biden wasted no time in implementing his plan to address a crisis that has caused the loss of more than 407,000 American lives.
Browse topics:
Link to MarketWatch's Slice.